Two stocks in Biotechnology
Oxford Nanopore Technologies vs Oxford Biomedica: profit, growth, debt and price compared
Oxford Nanopore Technologies is stronger on 3 of 6 figures: sales growth, debt and price trend. Oxford Biomedica is stronger on 1: profit margin.
Save both stocks to your watchlist and revisit their latest fundamentals.
| Oxford Nanopore TechnologiesONT.L | Oxford BiomedicaOXB.L | |
|---|---|---|
| Net margin | −51.7% | Stronger: −23.2% |
| Revenue growth, past year | Stronger: +10.50% | +9.00% |
| Debt to equity | Stronger: 9.9% | 273.1% |
| Forward P/E | Loss | Loss |
| Dividend yield | — | — |
| Analysts | Buy · 12 | Buy · 8 |
| From its 200-day average | Stronger: +22.8% | −5.2% |
Share price over the past year
- Oxford Nanopore Technologies+58.4%
- Oxford Biomedica−13.2%
20 Nov 202518 Nov 2026
Oxford Nanopore Technologies or Oxford Biomedica: which is stronger?
- OXB.L
Which is more profitable?
Oxford Biomedica keeps more of each sale as profit: −23.2% against −51.7%.
- ONT.L
Which is growing its sales faster?
Oxford Nanopore Technologies is growing its sales faster: +10.50% over the past year, against +9.00%.
- ONT.L
Which has borrowed less?
Oxford Nanopore Technologies has borrowed less: its debt is 9.9% of what its shareholders own, against 273.1% for Oxford Biomedica.
Which costs less for the profit it is expected to make?
Both are expected to make a loss over the next year.
Which pays more in dividends?
Neither pays a dividend.
Which do analysts rate higher?
Analysts rate both the same: Buy.
- ONT.L
Which is in the stronger price trend?
Oxford Nanopore Technologies' price is in the stronger trend: 22.8% above its 200-day average, against 5.2% below.
What each company does
ONT.LOxford Nanopore Technologies
Oxford Nanopore Technologies plc researches, develops, manufactures, and commercializes DNA and RNA sequencing technology.
Reports results on 3 March 2027
OXB.LOxford Biomedica
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide.
Reports results on 25 March 2027
This comparison is just the starting point.
Discover opportunities, understand companies and compare investments in one place. See how StratDeck works
Keep researching
Where next
More comparisons
Free email
Up to speed in minutes, four times a week
Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.
Early access
Become a StratDeck founding user
Use StratDeck, tell us what's missing, and help decide what we build next.
100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.